MétaCan
Menu
← Back to cohort

Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): Insights by <i>PTEN</i> status.

2025· article· en· W4410811469 on OpenAlexaff
Dana E. Rathkopf, Danni Zhao, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Hélène von Bandemer, Weiyan Li

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsAstraZeneca (Canada)
Fundersnot available
KeywordsPTENMedicineProstate cancerOncologyOverall survivalInternal medicineHormoneMetastatic breast cancerCancerCancer researchBreast cancerPI3K/AKT/mTOR pathwayApoptosisBiology

Abstract

fetched live from OpenAlex

5096 Background: The loss of function of the tumor suppressor gene PTEN is associated with an increased risk of recurrence and poor clinical outcomes in advanced prostate cancer (PC). Current understanding of PTEN prevalence and pt characteristics, treatment patterns, and survival outcomes by PTEN status in mHSPC is limited. Methods: This cohort study used retrospective longitudinal data from the US-based deidentified Flatiron Health-Foundation Medicine mPC clinicogenomic database. Male pts diagnosed (dx) with mHSPC between January 1, 2018, and March 31, 2024, who underwent comprehensive genomic profiling of a solid tumor specimen were included. Pts with PTEN alterations were classified as PTEN -homs del (homozygous deletion, defined as a copy number variant [CNV]=0) or PTEN -mut (CNV=1, pathological short variant alterations or rearrangements). Pts without PTEN alterations identified were classified as PTEN -nonaltered. Pt characteristics and treatment patterns were descriptively analyzed. Kaplan-Meier survival probabilities for real-world overall survival (rwOS; unadjusted) were estimated by PTEN status ( PTEN -homs del, PTEN -mut, and PTEN -nonaltered). Results: Of 1630 included pts, 39.8% had tumors with PTEN alterations ( PTEN -homs del, 23.2%; PTEN -mut, 16.6%). Overall, pts were predominantly non-Hispanic White with a mean (SD) age of 69 (9.1) years at mHSPC dx. At initial dx, 66.7% presented with a Gleason score of 8 to 10, and 68.1% had de novo metastatic disease. Median (IQR) prostate-specific antigen level (ng/mL) at metastatic diagnosis was lower in PTEN -homs del (47 [9-193]) and PTEN -mut (42 [11-157]) mHSPC relative to PTEN -nonaltered (68 [15-337]) mHSPC. BRCA mutations were less frequent in PTEN -homs del (6.1%) tumors relative to PTEN -mut (9.6%) and PTEN -nonaltered (10.3%) tumors. All other pt characteristics were generally similar across PTEN groups. The most common first-line treatments across all PTEN groups were ADT alone and ARPI ± ADT. Median (95% CI) rwOS (months) was 29.0 (24.1-33.6) in PTEN -homs del, 32.7 (27.8-37.9) in PTEN -mut, and 42.3 (38.7-46.0) in PTEN -nonaltered mHSPC groups. Pts with PTEN alterations tended to have lower landmark survival probabilities than pts without PTEN alterations (Table). Conclusions: Among pts with mHSPC, worse survival was observed in pts with tumors harboring PTEN alterations relative to pts without PTEN tumor alterations, despite similar pt characteristics and treatment patterns across PTEN groups. rwOS probability, % (95% CI) PTEN -homs del (n=378) PTEN -mut (n=271) PTEN -nonaltered (n=981) 12 month 81.6 (76.0-87.6) 83.9 (77.9-90.4) 90.7 (88.2-93.4) 24 month 56.8 (50.6-63.7) 64.4 (57.5-72.0) 73.8 (70.3-77.4)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.069
GPT teacher head0.446
Teacher spread0.377 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→